Danish Oil and Gas Stock News

Novo Nordisk (CPSE:NOVO B) received FDA approval for Wegovy as the first oral GLP-1 weight-loss medication and is launching the pill for commercial use. The company expanded its partnership with Aspect Biosystems to develop allogeneic cell therapies aimed at treating diabetes. Both moves extend Novo Nordisk's presence in obesity care and diabetes therapies beyond injectable drugs. Novo Nordisk, long known for its insulin and GLP-1 injection portfolio, is now adding an oral GLP-1 weight-loss...

If you are wondering whether Novozymes is attractively priced or looking stretched at today’s levels, you are in the right place for a clear, valuation focused rundown of the stock. The share price last closed at DKK 412.0, with returns of 2.6% over the past year and 25.2% over three years. Shorter term moves include a 2.4% decline over 7 days, a 1.8% gain over 30 days, and a 3.8% return year to date. Recent news coverage around Novozymes has largely centered on its role in specialty enzymes...

Ørsted has completed installation of the final wind turbine at its 920 MW Greater Changhua 2b and 4 offshore wind farms in Taiwan, a key milestone for the Asia-Pacific offshore wind industry. The project is the first in the region to supply renewable electricity under a corporate power purchase agreement, with full commercial operations expected in Q3 2026. We will now examine how completing the final turbine installation and progressing toward commercial operations shapes Ørsted’s broader...

Key Insights Per Aarsleff Holding's estimated fair value is kr.860 based on 2 Stage Free Cash Flow to Equity Current...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Demant fair value estimate is kr.302 Current share price of...

Novo Nordisk (CPSE:NOVO B) has expanded its partnership with Canadian biotech Aspect Biosystems to develop advanced cell based therapies for diabetes. The deal deepens Novo Nordisk's push into off the shelf cellular medicines that aim for disease modifying and potentially curative treatment options. Aspect Biosystems gains rights to key stem cell and hypoimmune technologies, while Novo Nordisk increases investment and keeps future commercialisation options. The partnership integrates Novo...

Why Pandora’s 2025 Guidance Has Grabbed Investor Attention Pandora (CPSE:PNDORA) has put fresh numbers on the table, guiding for a Q4 2025 EBIT margin of around 33.5% and full year EBIT of about DKK 7.8b, with a group margin near 24%. This earnings outlook, presented on the Q4 2025 guidance call, gives readers clearer visibility on profitability expectations at a time when the share price has faced pressure over the past year. See our latest analysis for Pandora. The guidance comes after a...

Amylyx Pharmaceuticals’ decision to advance AMX0318, a GLP-1 receptor antagonist discovered with Gubra (CPSE:GUBRA), into development puts fresh attention on Gubra’s partnership model and its potential milestone and royalty stream. See our latest analysis for Gubra. The Amylyx milestone news comes after a mixed period for Gubra, with a 1 day share price return of 0.41% and a 90 day share price return of 4.96%. This is set against a year to date share price return of a 16.74% decline and a 1...

FLSmidth (CPSE:FLS) has been in focus after launching a share buy-back programme of up to DKK 1.4b, authorising the repurchase of as many as 4,600,000 shares, which is around 8% of its share capital. See our latest analysis for FLSmidth. The buy-back arrives after a strong run, with the 1-month share price return of 21.08% and year-to-date share price return of 18.39% adding to a 1-year total shareholder return of 48.45%. This indicates that momentum has been building over both shorter and...

Alm. Brand A/S has reported that its 2025 insurance service result reached DKK 1.91 billion, above its stated financial target, and the Board has proposed an ordinary dividend of DKK 0.66 per share alongside plans for a new DKK 1.5 billion share buyback programme in 2026. This combination of exceeding internal performance goals and committing around DKK 2.4 billion to dividends and repurchases highlights a strong focus on shareholder returns. With Alm. Brand pairing a solid 2025 insurance...

NKT (CPSE:NKT) is back in focus after confirming final contracts with SSEN Transmission for two 525 kV HVDC cable projects in Scotland, adding about €2b of turnkey work to its high voltage backlog. See our latest analysis for NKT. The latest HVDC contract win and recent product launch around dry type high voltage terminations come against a backdrop of a 10.63% 90 day share price return and a 5 year total shareholder return of 236.01%. This suggests momentum has been building over time...

Recent performance snapshot A.P. Møller - Mærsk (CPSE:MAERSK B) has seen mixed short term returns, with a gain of about 1.1% over the past day, a 5.5% decline over the past week, and a 2.9% rise over the past month. Looking a bit further back, the stock shows a 15.4% return over the past 3 months and around 0.6% year to date. The 1 year total return stands at about 56.0%. See our latest analysis for A.P. Møller - Mærsk. At a share price of DKK 14,860, A.P. Møller - Mærsk combines a recent dip...

Tryg (CPH:TRYG) has had a rough month with its share price down 1.6%. However, the company's fundamentals look pretty...

One thing we could say about the covering analyst on cBrain A/S ( CPH:CBRAIN ) - they aren't optimistic, having just...

RIAS A/S ( CPH:RIAS B ) has announced that on 26th of January, it will be paying a dividend ofDKK26.00, which a...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...

To the annoyance of some shareholders, Pandora A/S ( CPH:PNDORA ) shares are down a considerable 26% in the last month...

What Novo Nordisk’s recent performance data tells you Novo Nordisk (CPSE:NOVO B) has seen mixed share performance recently, with about a 3% decline over 1 day, a broadly flat past week, and gains over the past month and past 3 months. See our latest analysis for Novo Nordisk. At a share price of DKK 377.55, Novo Nordisk’s recent 21.79% 1 month share price return contrasts with a weaker 1 year total shareholder return of 29.56% and a stronger 5 year total shareholder return of 83.01%. This...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Amylyx Pharmaceuticals recently selected AMX0318, a long-acting GLP-1 receptor antagonist discovered in collaboration with Gubra, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a US$4,000,000 milestone payment and positioning Gubra for more than US$50,000,000 in potential future milestones plus mid-single digit royalties. The move underlines how Gubra’s partnered peptide programs can translate preclinical research into tangible milestone income...

Ambu A/S recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, highlighting its single-use endoscopy focus and turnaround progress. The company used the conference platform to showcase innovation, scalable operations, and an improved financial outlook that could influence how investors view its recovery narrative. Next, we examine how Ambu’s emphasis on single-use endoscopy leadership and turnaround progress at the conference shapes its investment...

Hove A/S ( CPH:HOVE ) shares have continued their recent momentum with a 27% gain in the last month alone. The annual...

Brd. Klee A/S ( CPH:KLEE B ) is about to trade ex-dividend in the next three days. The ex-dividend date generally...

Genmab A/S recently reported topline Phase 3 EPCORE DLBCL-1 data showing that subcutaneous epcoritamab monotherapy improved progression-free survival versus standard chemo‑immunotherapy in previously treated, transplant‑ineligible diffuse large B‑cell lymphoma patients, with safety consistent with its known profile. This is the first Phase 3 trial to show a progression-free survival benefit for a CD3xCD20 bispecific antibody used as monotherapy in relapsed or refractory diffuse large B‑cell...